GPX2, a key molecule of the glutathione redox system that acts in concert to provide a coordinated network of protection against ROS accumulation and oxidative damage, has been suggested as a prognostic marker in CRPC, and its silencing is able to inhibit prostate cancer growth [52]. Here, GPX2 is linked to prostate carcinoma.